Floatz logo

Vts-K

Major Depressive Disorder

Theresa Jacob, PhD, MPHPhase 4 / ApprovedActive
B
58/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
65/ 100

Competitive context

234 Active assets in the Major Depressive Disorder cohort.

Asset / SponsorPhaseRating
Risperdal
Johns Hopkins University
Phase 4BBB
Zelapar
Corium Innovations, Inc.
Phase 4BBB
S-Ketamine
Janssen Research & Development, LLC
Phase 4BBB
EDIVOXETINE
Eli Lilly and Company
Phase 3BBB
Opc-34712
Nova Scotia Health Authority
Phase 4BBB

View all 50 →

Same molecule, other indications

Vts-K is also rated in:

Central Nervous System DepressantsDormant
BB
Indicative ·
69 / 100
View asset →
Peripheral Nervous System AgentsDormant
BB
Indicative ·
69 / 100
View asset →
Anti-Inflammatory AgentsDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →